Krystal Biotech (KRYS) Assets Average (2017 - 2026)

Krystal Biotech (KRYS) has 10 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 28.19% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 28.19% YoY), and the FY2025 full-year result was $1.2 billion, up 27.5% from the prior year.
• Assets Average advanced to $1.4 billion in Q1 2026, from $1.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2026 to a low of $545.1 million in Q1 2023.
• A 5-year average of $869.7 million and a median of $835.8 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 64.91% in 2022 and declined 12.3% in 2023, its largest moves.
• Tracing KRYS's Assets Average over 5 years: stood at $567.4 million in 2022, then surged by 41.76% to $804.4 million in 2023, then rose by 26.7% to $1.0 billion in 2024, then grew by 26.29% to $1.3 billion in 2025, then climbed by 6.09% to $1.4 billion in 2026.
• Business Quant data shows KRYS's Assets Average at $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.